A targeted enzyme approach to sensitization of tyrosine kinase inhibitor-resistant breast cancer cells

Experimental Cell Research

Volumn 318, Issue 16, 2012, Pages 2014-2021

  Giordano, Courtney R ^a   Mueller, Kelly L ^a   Terlecky, Laura J ^a   Krentz, Kendra A ^a   Bollig Fischer, Aliccia ^a,b   Terlecky, Stanley R ^a   Boerner, Julie L ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Breast cancer; Epidermal growth factor receptor; Reactive oxygen species; Tyrosine kinase; Tyrosine kinase inhibitors

Indexed keywords

CATALASE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; REACTIVE OXYGEN METABOLITE;

ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; DRUG SENSITIZATION; DRUG TREATMENT FAILURE; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84864308018     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.06.001     Document Type: Article

References (27)

1. DeYulia G.J., Carcamo J.M. EGF receptor-ligand interaction generates extracellular hydrogen peroxide that inhibits EGFR-associated protein tyrosine phosphatases. Biochem. Biophys. Res. Commun. 2005, 334(1):38-42.
2. Jorissen R.N., et al. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp. Cell Res. 2003, 284(1):31-53.
3. Baselga J., et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J. Clin. Oncol. 2005, 23(23):5323-5333.
4. Tan A.R., et al. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J. Clin. Oncol. 2004, 22(15):3080-3090.
5. Mueller K.L., Hunter L.A., Ethier S.P., Boerner J.L. Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res. 2008, 68(9):3314-3322.
6. Irwin M.E., Mueller K.L., Bohin N., Ge Y., Boerner J.L. Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J. Cell Physiol. 2011, 226(9):2316-2328.
7. Wheeler D.L., Dunn E.F., Harari P.M. Understanding resistance to EGFR inhibitor-impact on future treatment strategies. Nat. Rev. Clin. Oncol. 2010, 7(9):493-507.
8. Lo H.W. EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance. Curr. Mol. Pharmacol. 2010, 3(1):37-52.
9. Amos S., Martin P.M., Polar G.A., Parsons S.J., Hussaini I.M. Phorbol 12-myristate 13-acetate induces epidermal growth factor receptor transactivation via protein kinase Cdelta/c-Src pathways in glioblastoma cells. J. Biol. Chem. 2005, 280(9):7729-7738.
10. Stover D.R., Becker M., Liebetanz J., Lydon N.B. Src phosphorylation of the epidermal growth factor receptor at novel sites mediates receptor interaction with Src and P85 alpha. J. Biol. Chem. 1995, 270(26):15591-15597.
11. Spivak-Kroizman T., et al. Heterodimerization of c-erbB2 with different epidermal growth factor receptor mutants elicits stimulatory or inhibitory responses. J. Biol. Chem. 1992, 267(12):8056-8063.
12. Wang S.E., et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006, 10(1):25-38.
13. Chen C.H., et al. Reactive oxygen species generation is involved in epidermal growth factor receptor transactivation through the transient oxidization of Src homology 2-containing tyrosine phosphatase in endothelin-1 signaling pathway in rat cardiac fibroblasts. Mol. Pharmacol. 2006, 69(4):1347-1355.
14. Benhar M., Engelberg D., Levitzki A. ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep. 2002, 3(5):420-425.
15. Bollig-Fischer A., et al. HER-2 signaling, acquisition of growth factor independence, and regulation of biological networks associated with cell transformation. Cancer Res. 2010, 70(20):7862-7873.
16. Liou G.Y., Storz P. Reactive oxygen species in cancer. Free Radical Res. 2010, 44(5):479-496.
17. Lee S.R., Kwon K.S., Kim S.R., Rhee S.G. Reversible inactivation of protein-tyrosine phosphatase 1B in A431 cells stimulated with epidermal growth factor. J. Biol. Chem. 1998, 273(25):15366-15372.
18. Koepke J.I., et al. Restoration of peroxisomal catalase import in a model of human cellular aging. Traffic 2007, 8(11):1590-1600.
19. Undyala V., Terlecky S.R., Vander Heide R.S. Targeted intracellular catalase delivery protects neonatal rat myocytes from hypoxia-reoxygenation and ischemia-reperfusion injury. Cardiovasc. Pathol. 2011, 20(5):272-280.
20. Young C.N., et al. Reactive oxygen species in tumor necrosis factor-alpha-activated primary human keratinocytes: implications for psoriasis and inflammatory skin disease. J. Invest. Dermatol. 2008, 128(11):2606-2614.
21. Terlecky S.R. In vitro analysis of peroxisomal protein import. Curr. Protocol Cell Biol. 2002, 15. (Chapter 11:Unit 11).
22. Terlecky S.R., Legakis J.E., Hueni S.E., Subramani S. Quantitative analysis of peroxisomal protein import in vitro. Exp. Cell Res. 2001, 263(1):98-106.
23. Legakis J.E., et al. Peroxisome senescence in human fibroblasts. Mol. Biol. Cell 2002, 13(12):4243-4255.
24. Price M., Terlecky S.R., Kessel D. A role for hydrogen peroxide in the pro-apoptotic effects of photodynamic therapy. Photochem. Photobiol. 2009, 85(6):1491-1496.
25. Terlecky S.R., Koepke J.I. Drug delivery to peroxisomes: employing unique trafficking mechanisms to target protein therapeutics. Adv. Drug Deliv. Rev. 2007, 59(8):739-747.
26. Wood C.S., et al. Hypocatalasemic fibroblasts accumulate hydrogen peroxide and display age-associated pathologies. Traffic 2006, 7(1):97-107.
27. Tonks N.K. Protein tyrosine phosphatases: from genes, to function, to disease. Nat. Rev. Mol. Cell Biol. 2006, 7(11):833-846.